MR imaging guidelines for Medtronic DBS systems listed the following control measures for minimizing the risks during MR imaging: 1) use 1.5-T MR imaging systems; 2) use a transmit/receive RF head coil; 3) use a receive-only head coil or head transmit coil; 4) do not exceed a head SAR value of 0.1 W/kg; and 5) limit the gradient switching (dB/dt) to ≤ 20 T/sec. Despite these recommendations, many radiology centers do not perform MR imaging procedures on patients with implanted devices, believing that the presence of a ferromagnetic device is a contraindication for MR imaging. The increasing role of MR imaging in the care of patients and the recently published adverse events in 2 patients treated with DBS during MR imaging examinations indicate the need to define specific safety guidelines and the importance for physicians who care for these patients to be aware of the risks and recommendations. 7, 10 The purpose of this study was to share our clinical experience regarding the effects of MR imaging on the electrical settings of implanted DBS devices and their clinical consequences.
Methods

Patient Population and DBS System
From January 1987 to March 2009, 570 patients were treated with DBS for movement disorders at our center. All patients received the same implanted neurostimulation system used to treat movement disorders (Activa, Medtronic). This system included 1 or more leads of different models (monopolar lead SP-5535 [currently the 3388 series] or the quadripolar DBS lead models 3387 and 3389), depending on the date of implant, and were composed of iridium and platinum. These leads were connected through lead extensions to a single-channel (Itrel I, II, or Soletra; Medtronic) or a dual-channel (Kinetra, Medtronic) IPG, which had titanium cases. The IPG was implanted subcutaneously in the subclavicular region. The excess lead length was coiled in 1 loop at the parietal scalp level, and the excess length of the extension lead was wrapped once around the IPG.
Magnetic Resonance Imaging
Before the implantation of the lead extension and neurostimulator, all patients underwent brain MR imaging 1-3 days after DBS lead implantation to check lead location. Among the patients we prospectively studied between 2000 and 2008, some required additional MR imaging scans for different medical conditions. For these patients, the MR imaging scan was performed with the entire DBS system implanted, including the leads, lead extensions, and IPG. The MR imaging scans were performed using either a Philips Gyroscan ACS II 1.0-T or 1.5-T scanner, using a transmit body RF coil and receive-only head RF coil. Cerebral MR imaging consisted of a survey scan (SAR < 0.1 W/kg), 3D fast field echo T1-weighted images (SAR < 0.4 W/kg), and spin echo T2-weighted images in coronal (SAR < 1.2 W/kg) and sagittal (SAR < 2.4 W/kg) planes. Spinal MR imaging consisted of a survey scan (SAR < 0.1 W/ kg), spin echo T1-weighted images in the sagittal and axial planes (SAR < 4.0 W/kg) before and after Gd injection, and spin echo T2-weighted images in the sagittal plane (SAR < 2.7 W/kg). The neurostimulators were switched off and the voltage was set to 0 before the MR imaging scan. The pulse width, DBS frequency, and stimulation mode (bipolar or unipolar) that were used long term remained the same. The magnet-activated reed switch of the dual-channel Kinetra IPG was disabled, and the reed switch of the single-channel Itrel II IPG was set to "normal amplitude." This function was not available on the single-channel Soletra IPG.
The electrical parameters, including the measurement of battery current in unipolar mode and impedances with nominal electrical parameters for each electrode (3.0 V, 210 μsec, 30 Hz), were recorded and printed out before and after the MR imaging examinations to determine whether or not the settings were modified during the examination. Patients were monitored continuously by a neurologist and a radiologist through verbal and visual contact during the procedure and were asked to report any unusual signs or discomfort. At the end of the procedure, the sites where the devices were implanted (scalp, cervical, and subclavicular regions) were examined and any local change was reported. The previously used electrical DBS parameters were reprogrammed after the end of the procedure. Patients were informed of the potential risks of MR imaging and gave their informed consent before the examination.
Results
From 2000 to 2008, 31 patients treated with DBS for movement disorders underwent a total of 61 MR imaging scans at our center (57 for brain MR imaging, 4 for spinal MR imaging; Table 1 ) with the entire DBS system implanted. Of these 31 patients, 25 had Parkinson disease, 5 had dystonia, and 1 had essential tremor. Seven of the 61 additional MR imaging procedures were performed within the first 3 months after DBS implantation; the remaining 54 scans were performed a mean of 4.9 ± 2.7 years after DBS implantation. The medical indications for the MR imaging examinations are listed in Table 1 . None of the patients reported any unusual signs that would have required a premature termination of the MR imaging during the procedure or after the end of the session. We found no break in the lead wires on the MR images. The clinical effects of DBS on movement disorders remained unchanged after reprogramming the IPG with previously used electrical settings. Thirty-eight Itrel II IPG models, 22 Kinetra models, and 1 Soletra IPG were tested. These IPGs were connected to either monopolar leads (3 total), or quadripolar leads (DBS model 3387, 13 total; DBS model 3389, 65 total) implanted in the STN in 51 cases, the GPi in 20 cases, and the Vim in 12 cases. Some patients had a single lead, most had 2 leads, and several had multiple implanted leads. The effects of the MR imaging procedure on the IPG settings are reported in Table 2 . No changes in the voltage, pulse width, DBS frequency, or impedances were observed, regardless of the IPG model used. We recorded 29 IPG output activations with the Itrel II model, 22 of which were switched on, but no output activation with the Soletra and the Kinetra models. Nineteen of the 38 Itrel II IPGs switched from the "normal amplitude" to the "magnet amplitude" setting at a range of 1-672 magnet activations (mean 37.5 ± 128.8 ac-tivations) during the MR imaging procedure. The magnetactivated reed switch function of the Kinetra IPG remained disabled during the MR imaging procedure.
Discussion
The increasing use of MR imaging raises concern for its safety in patients treated with DBS. Potential risks associated with MR imaging procedures in patients with implanted electrical devices include induced heating of electrodes and surrounding brain tissue, magnetic field interactions, lead displacement risk, induced electrical current, and functional disruption of the device. 1, 12, 18 Most in vitro experiments examined the induced electrical current and MR-induced heating for different stimulation systems using different designs of phantom models. 2, 3, 6, [12] [13] [14] These studies showed that the amount of induced electrical currents and temperature increases varied from 2.5 to 63.1°C, and depended on: 1) the field strength and RF of the MR imaging system; 2) the type of transmit RF coil; 3) the amount of RF energy calculated as the SAR; 4) the anatomical region of interest; and 5) the type, configuration, and electrical characteristics of the stimulation system. Several severe adverse events were reported in patients with implanted DBS systems, who were exposed to RF and developed heating-induced lesions of the brain. In 1 case, the patient had externalized leads and developed transient but disabling dyskinesia after 1.0-T brain MR imaging performed with a head transmit RF coil. 15 The other 2 severe permanent neurological deficits occurred in patients with the entire Activa Therapy system implanted, during 1.0-T spine MR imaging with a body transmit RF coil in 1 case and during diathermy treatment close to the extension lead in the other case. 7, 10 In the present study, we attempted to determine the effects of different MR imaging procedures on a DBS system in patients with movement disorders. No clinical adverse events occurred during or after the MR imaging procedure and patients reported neither discomfort nor other subjective sensations. We observed no change in the electrical parameters of the Soletra and Kinetra IPGs used for the procedure. We observed several activations of the reed switch function and output activations of the IPG with the Itrel II model, with no clinical or electrical consequences, as the voltage was set to 0 V before the procedure. Even though RF-induced severe adverse events mainly occurred in patients with implanted neurostimulators, most studies have addressed MR safety issues for patients with implanted leads only.
Three recently published retrospective studies reviewed the safety of MR imaging in patients with movement disorders treated using DBS. 4, 9, 16 In the largest survey, more than 3000 patients from 23 of 42 centers involved in DBS programs underwent brain MR imaging after the implantation of 1 or more DBS leads. 16 No clinical adverse effects were reported after 1071 MR imaging events performed at a single center using 1.5-T MR imaging and SAR ≤ 3 W/kg in 405 patients treated with 746 implanted DBS systems at a single center, and after 226 MR imaging procedures in 161 patients at another center. 4, 9 Most centers currently performing MR imaging in patients with DBS obtain these images in patients with the entire DBS system implanted. 16 However, only a small number of in vivo studies have reported the effects of MR procedures on the entire implanted DBS system, including leads, extension leads, and IPGs. 5, 8, 9, 17 Details about the neurosurgical technique, MR imaging procedures, number of MR imaging scans, IPG model, and DBS operating mode during the MR imaging procedure may be missing or differ from one study to the other and limit the interpretation of the collected data. No hardwarerelated complications were reported with Itrel II or III IPG models in 38 patients who underwent 50 brain or In another study, no clinical adverse events were reported in 405 patients who underwent 1041 MR imaging events with the entire DBS system implanted, but the effects on the electrical settings of the neurostimulators were not reported. 9 One IPG failure was reported in the largest published series of patients undergoing MR imaging with an implanted DBS system, but the number of MR imaging examinations performed in these patients with implanted neurostimulators was not reported. 16 Another IPG failure and 1 IPG reset during 66 MR imaging procedures was reported in a study involving Itrel III IPG models with no further clinical consequences after replacement of the devices. 4 In our study, the Kinetra IPG model appeared to be particularly safe because the magnet reed switch function can be disabled during the procedure, preventing any change in the IPG electrical settings and thus any discomfort for the patient. The ability to disable the magnetactivated reed switch function on the Kinetra IPG made it insensitive to magnetic fields up to 1.5 T in our study.
Conclusions
Our data confirm that, under the same configuration of the entire implanted DBS system and with careful monitoring, MR imaging examinations at 1.5 T could be performed with minimal risk and no damage to the implanted devices. These results cannot be extrapolated to devices other than those tested. The need to arrest the stimulation device is an important practical limitation, restricting the use of MR imaging to centers that are familiar with the DBS device. Widespread use of MR imaging cannot be recommended in patients with DBS systems. The increasing number of medical indications using DBS to treat movement disorders or other related disorders, and the emerging new devices from several manufacturers, increases the need for detailed and specific guidelines for safe use of MR imaging with neurostimulation systems.
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